Abstract
A variety of classical machine learning (ML) approaches have been developed over the past decade aiming to individualize drug dosages based on measured plasma concentrations. However, the interpretability of these models is challenging as they do not incorporate information on pharmacokinetic (PK) drug disposition. In this work we compare drug plasma concentraton predictions of well-known population PK (PopPK) modeling with classical machine learning models and a newly proposed scientific machine learning (MMPK-SciML) framework. MMPK-SciML lets us estimate PopPK parameters and their inter-individual variability (IIV) using multimodal covariate data of each patient and does not require assumptions about the underlying covariate relationships. A dataset of 541 fluorouracil (5FU) plasma concentrations as example for an intravenously administered drug and a dataset of 302 sunitinib and its active metabolite concentrations each, as example for an orally administered drug were used for analysis. Whereas classical machine learning models were not able to describe the data sufficiently, MMPK-SciML allowed us to obtain accurate drug plasma concentration predictions for test patients. In case of 5FU, goodness-of-fit shows that the MMPK-SciML approach predicts drug plasma concentrations more accurately than PopPK models. For sunitinib, we observed slightly less accurate drug concentration predictions compared to PopPK. Overall, MMPK-SciML has shown promising results and should therefore be further investigated as a valuable alternative to classical PopPK modeling, provided there is sufficient training data.
Competing Interest Statement
H.F. received grants from UCB and AbbVie. The other authors declare no competing interest for this work.
Funding Statement
This work was partially funded by Federal Ministry of Education and Research within the projects BNTrAinee (funding code 16DHBK1022).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The 5FU study (protocol-No: CESAR C-II-005, EudraCT-No; 2008-001515-37) with retrospective nature which was approved on 26.05.2008 by the ethics committee of the Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany. The C-IV-001 Sunitinib study (EudraCT-No: 2012-001415-23) was approved on 17.10.2012 by the ethics committee of the department of medicine of the Johann Wolfgang Goethe-Universitaet Frankfurt am Main, Frankfurt, Germany. It was a phase IV PK/PD substudy of the non-interventional EuroTARGET project, which recruited patients with mRCC at nine medical centres in Germany and the Netherlands
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* shared first authorship
↵# shared senior authorship
Funding: This work was partially funded by Federal Ministry of Education and Research within the project “BNTrAinee” (funding code 16DHBK1022).
Conflict of Interest: H.F. received grants from UCB and AbbVie. The other authors declare no competing interest for this work.
Notation was clarified and possible uses cases where added
Data Availability
Data used in the present study could be available upon reasonable request to the authors
